Protara Therapeutics Announces Promising Phase 2 Results for NMIBC Treatment TARA-002
Protara Therapeutics Inc. has announced promising Phase 2 results for its NMIBC treatment, TARA-002, showing a high complete response rate and favorable safety profile in two patient cohorts.
3 minutes to read